ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

AACR considering new office in D.C.

July 18, 2003

NCAB Approves Fallout Study On Split Vote

March 13, 1981

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

April 22, 2005

Generic Paclitaxel Approval Withstands Court Challenge.

May 4, 2001

Senate Subcommittee Gives NCI 41.397 Billion for FY ‘87

August 8, 1986

March Dedicated To Colorectal Cancer Awareness; New Advocacy Group.

March 10, 2000